SUBSCRIBE TODAY!
Subscribing entitles a reader to complete stories on all topics released as they happen, special features, confidential documents and access to the complete, searchable story archive online back to 2004.
IP-Watch Summer Interns

IP-Watch interns talk about their Geneva experience in summer 2013. 2:42.

Inside Views

Submit ideas to info [at] ip-watch [dot] ch!

We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

Quantitative Analysis Of Contributions To NETMundial Meeting

A quantitative analysis of the 187 submissions to the April NETmundial conference on the future of internet governance shows broad support for improving security, ensuring respect for privacy, ensuring freedom of expression, and globalizing the IANA function, analyst Richard Hill writes.


Latest Comments
  • Why should anyone care what James Anaya thinks? In... »
  • If this goes ahead, as the EU will "speak" for all... »

  • For IPW Subscribers

    A directory of IP delegates in Geneva. Read more>

    A guide to Geneva-based public health and intellectual property organisations. Read More >


    Monthly Reporter

    The Intellectual Property Watch Monthly Reporter, published from 2004 to January 2011, is a 16-page monthly selection of the most important, updated stories and features, plus the People and News Briefs columns.

    The Intellectual Property Watch Monthly Reporter is available in an online archive on the IP-Watch website, available for IP-Watch Subscribers.

    Access the Monthly Reporter Archive >

    Grupo de expertos considera que el acceso a los medicamentos seguros es una cuestión de salud pública y no de propiedad intelectual

    Published on 14 October 2009 @ 2:28 pm

    By , Intellectual Property Watch

    Las iniciativas de lucha contra la falsificación podrían dificultar el acceso a los medicamentos sin que se logre paliar el problema de los fármacos falsificados, en particular en los países en desarrollo, según dijeron miembros de un grupo de expertos en un evento organizado recientemente por el Open Society Institute.

    La confusión que existe entre los medicamentos genéricos legítimos, los medicamentos de mala calidad y aquellos que son copias ilegales de productos de marca registrada puede tener un impacto devastador, y es necesario contar con una mayor precisión en la definición y el alcance de la falsificación, añadieron los expertos.

    Según un documento de Médicos Sin Fronteras, los medicamentos falsificados son productos empacados con la intención de que parezcan legítimos, pero no lo son. Esto constituye una infracción de marca. Por otra parte, un fármaco deficiente es un producto fabricado legítimamente que no cumple con las normas establecidas por la respectiva autoridad encargada de la regulación de medicamentos. Esto se trata de una cuestión de control de calidad. Por último, un medicamento genérico es un fármaco producido legítimamente, igual al producto de marca original por lo general ya no amparado por una patente, y que contiene los mismos ingredientes activos.

    “Cuando hablamos de las iniciativas de lucha contra la falsificación, nos referimos básicamente a la agenda mundial de observancia en materia de propiedad intelectual”, comentó en la reunión del 25 de septiembre Sangeeta Shashikant, asesor jurídico superior de la Red del Tercer Mundo.

    En el plano nacional, se están impulsando medidas de aplicación de los derechos de PI en los países en desarrollo, especialmente en África, añadió Shashikant. En Kenya, por ejemplo, se aprobó un proyecto de ley contra la falsificación y en Uganda se está examinando la cuestión.

    Según Shashikant, el problema está en el ámbito de aplicación de dicha legislación. En el Acuerdo de la Organización Mundial del Comercio sobre los Aspectos de los Derechos de Propiedad Intelectual relacionados son el Comercio (ADPIC), la falsificación está definida como relativa a la infracción de marcas. El proyecto de ley de Kenya va más allá de los ADPIC y hace referencia a todas las infracciones de propiedad intelectual tales como patentes, marcas, derechos de autor, dibujos y modelos industriales, e incluso la protección de las obtenciones vegetales.

    La cuestión de la calidad de los fármacos debe ser tratada por las autoridades encargadas de la regulación de medicamentos, y no por las autoridades aduaneras, puesto que los funcionarios de aduanas no están en capacidad de determinar si un producto está infringiendo los derechos de propiedad intelectual, comentó Shashikant, y añadió que los casos relacionados con la violación de estos derechos deben ser tratados por las oficinas de propiedad intelectual.

    Los funcionarios de aduanas no tienen la capacidad para evaluar la calidad de un medicamento, de acuerdo con Partha Satpathy, Consejero de la Misión Permanente de la India. La mera sospecha por parte del titular de los derechos de propiedad intelectual puede llevar a que los bienes sean incautados en la frontera y detenidos durante meses, dijo Shashikant. Esto sucedió varias veces en Europa el año pasado, principalmente en los Países Bajos.

    No debe haber confusión entre los fármacos deficientes y los medicamentos genéricos, aunque a veces hay un intento deliberado de perpetuar esta confusión, comentó Elio Cardoso, Consejero de la Misión Permanente del Brasil.

    Todos los participantes coincidieron en el hecho de que no conviene incluir la cuestión del acceso a medicamentos seguros en un marco de PI sino que debe abordarse en el marco de la salud pública. “El asunto del acceso a los medicamentos en la Organización Mundial de la Salud debe examinarse en el ámbito de la salud pública y no en el de propiedad intelectual”, dijo Cardoso.

    Para Michelle Childs de Médicos Sin Fronteras, la cuestión radica en tener acceso a tratamientos existentes, así como también a nuevos tratamientos. La legislación de la India cuenta ahora con nuevas normas de PI y algunos nuevos fármacos para el tratamiento del VIH están amparados por patentes, dificultando así el acceso a nuevos medicamentos, dijo.

    Catherine Saez may be reached at info@ip-watch.ch.

     


    Leave a Reply

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website. By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

    By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

    2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

    3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

    4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

    5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

    6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

    7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

    8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

    9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

     

     
    Your IP address is 182.118.21.252